Skip to content

Effects of hyperbaric oxygen combined with incentive spirometer on pulmonary dysfunction after COVID-19 infection

Effects of hyperbaric oxygen combined with incentive spirometer on pulmonary dysfunction after COVID-19 infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070923
Enrollment
Unknown
Registered
2023-04-26
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group of Hyperbaric oxygen treatment:Hyperbaric oxygen treatment
Group of incentive spirometer :using incentive spirometer
Group of Hyperbaric oxygen combined with incentive spirometer:Hyperbaric oxygen combined with incentive spirometer

Sponsors

General Hospital of Southern Theater Command of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Previous COVID-19 antigen or nucleic acid positive, according to the "novel coronavirus diagnosis and Treatment Protocol (trial 10th edition)" issued by the National Health Commission, in line with mild or moderate infection; ? Within 60 days after COVID-19 infection (antigen or nucleic acid positive); ? Education level in primary school or above; (4) Subjectively receiving HBO treatment without absolute contraindications for hyperbaric oxygen treatment (1) untreated pneumothorax; 2. Taking disulfiram (C10H20N2S4); 3. Taking antitumor drugs such as bleomycin, cisplatin and doxorubicin simultaneously; 4. Premature and/or low birth weight newborns.) ; (5) Subjectively receiving respiratory trainers and no contraindications (including clinical instability and uncontrolled infection); Severe pulmonary hypertension or congestive heart failure, respiratory failure; Other clinical conditions that may aggravate the condition during training, such as unstable angina pectoris and recent myocardial infarction; Cognitive dysfunction; Obvious abnormal liver function; Carcinoma metastasis; Recent spinal injury, rib fracture, hemoptysis.) .

Exclusion criteria

Exclusion criteria: ? History of severe COPD, pulmonary tuberculosis, asthma, craniocerebral trauma, encephalitis, cerebrovascular accident, myocardial infarction, heart failure, pulmonary heart disease and malignant tumor; ? Cognitive impairment, consciousness impairment, long-term history of alcohol abuse, mental illness or drug abuse; ? Age =17 years old or =66 years old; ? Patients are unable or unwilling to undergo examination or treatment.

Design outcomes

Primary

MeasureTime frame
Pulmonary function test;

Secondary

MeasureTime frame
Questionnaire scale evaluation;

Countries

China

Contacts

Public ContactXiaoxiao Ni

General Hospital of Southern Theater Command of PLA

nxx373@hotmail.com+86 20 88686708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026